Sedogen Receives U.S. Patent for Diazoxide Treatment of Prader-Willi Syndrome Behavioral Symptoms

Key Takeaways

• Sedogen LLC received U.S. Patent 12,589,098 for diazoxide formulations to treat behavioral symptoms in Prader-Willi syndrome
• The patent covers treatment of food-related behavioral symptoms and preoccupation with food in PWS patients
• This intellectual property protection strengthens Sedogen’s position in the rare disease market for PWS therapeutics

---

Sedogen Secures Patent Protection for PWS Treatment

CHICAGO, April 15, 2026 — Sedogen LLC, a biopharmaceutical company focused on Prader-Willi syndrome (PWS) treatments, announced the U.S. Patent and Trademark Office has issued patent number 12,589,098 for pharmaceutical formulations of diazoxide to reduce behavioral symptoms in PWS patients.

Patent Covers Food-Related Behavioral Symptoms

The newly issued patent specifically protects the use of diazoxide formulations to address challenging behavioral symptoms associated with Prader-Willi syndrome, particularly food-related behaviors and preoccupation with food that significantly impact patients and families.

Prader-Willi syndrome is a rare genetic disorder affecting approximately 1 in 15,000 births, characterized by hyperphagia (excessive eating), behavioral challenges, and developmental delays. Current treatment options remain limited, creating significant unmet medical needs for PWS families.

Diazoxide’s Mechanism in PWS Treatment

Diazoxide, traditionally used for hypoglycemia treatment, works by opening potassium channels and has shown potential in addressing the complex behavioral manifestations of PWS. The patent protection covers specific formulations designed to optimize therapeutic outcomes for behavioral symptom management.

Market Impact and Competitive Position

This patent strengthens Sedogen’s intellectual property portfolio in the rare disease space, potentially providing market exclusivity for diazoxide-based PWS treatments. The rare disease market for PWS therapeutics represents a significant opportunity, with limited approved therapies currently available.

The patent issuance follows growing interest in repurposing existing medications for rare disease applications, where traditional drug development timelines and costs can be prohibitive.

Next Steps for Development

While the patent provides important intellectual property protection, Sedogen will need to advance clinical development programs to demonstrate safety and efficacy in PWS patients. The company has not disclosed specific timelines for clinical trials or regulatory submissions.

This patent represents a significant milestone for Sedogen’s PWS program and highlights the potential for innovative approaches to address unmet needs in rare genetic disorders.

---

Frequently Asked Questions

What does this patent mean for Prader-Willi syndrome patients?

The patent protects Sedogen’s right to develop diazoxide formulations for PWS behavioral symptoms, potentially leading to new treatment options, though clinical trials are still needed to prove safety and effectiveness.

When will diazoxide be available for PWS treatment?

No timeline has been announced. Sedogen must still conduct clinical trials and obtain FDA approval before diazoxide formulations can be prescribed for PWS behavioral symptoms.

How does diazoxide compare to current PWS treatments?

Current PWS treatments are limited and primarily focus on growth hormone therapy and symptom management. Diazoxide would represent a novel approach specifically targeting behavioral symptoms if successfully developed.

Related coverage

• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment